ReviewInternational journal of molecular sciences2017
An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 209 citations in OpenAlex.
- Mitochondrial DNA Damage Induced by Aristolochic Acid I: Recognizing the Heart as a Target Organ.Chemical research in toxicology · 2026Article
- Sex-specific toxicity targets of aristolochic acids: nephrotoxicity in males, hepatotoxicity in females.Archives of toxicology · 2026Article
- Article
- Cross-Instrument Data Utilization Based on Laser-Induced Breakdown Spectroscopy (LIBS) for the Identification ofBioengineering (Basel, Switzerland) · 2025Article
- Analysis of Honey and Environmental Samples from BEN Endemic Villages in Serbia: Identification of a Novel Human Exposure Pathway for Aristolochic Acids and Aristolactams.Journal of agricultural and food chemistry · 2025Article
- The Double-Edge Sword of Natural Phenanthrenes in the Landscape of Tumorigenesis.Molecules (Basel, Switzerland) · 2025Review
- Absorptivity Is an Important Determinant in the Toxicity Difference between Aristolochic Acid I and Aristolochic Acid II.Journal of agricultural and food chemistry · 2025Article
- Molecular pharmacokinetic mechanism of JBP485 against aristolochic acid I (AAI) -induced nephrotoxicity.Frontiers in pharmacology · 2025Article
- Global transcriptome modulation by xenobiotics: the role of alternative splicing in adaptive responses to chemical exposures.Human genomics · 2024Article
- Chronic renal impairment predicts oncological outcomes in UTUC patients undergoing RNU.BMC urology · 2024Article
- Article
- Knockout of integrin αvβ6 protects against renal inflammation in chronic kidney disease by reduction of pro-inflammatory macrophages.Cell death & disease · 2024Article
- LYC inhibits the AKT signaling pathway to activate autophagy and ameliorate TGFB-induced renal fibrosis.Autophagy · 2024Article
- Article
- No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.Chinese journal of integrative medicine · 2024Article
- SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.American journal of physiology. Renal physiology · 2024Article
- Assessment of Retinal Microangiopathy in Patients with Balkan Endemic Nephropathy Using Optical Coherence Tomography Angiography-A Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Identification and analysis of differently expressed transcription factors in aristolochic acid nephropathy.Environmental health and preventive medicine · 2024Article
- Aristolochic acid induces acute kidney injury through ferroptosis.Frontiers in pharmacology · 2024Article
- Detection and Removal of Aristolochic Acid in Natural Plants, Pharmaceuticals, and Environmental and Biological Samples: A Review.Molecules (Basel, Switzerland) · 2023Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term "aristolochic acid nephropathy" (AAN) is used to include any form of toxic interstitial nephropathy that is caused either by ingestion of plants containing aristolochic acids (AA) as part of traditional phytotherapies (formerly known as "Chinese herbs nephropathy"), or by the environmental contaminants in food (Balkan endemic nephropathy). It is frequently associated with urothelial malignancies. Although products containing AA have been banned in most of countries, AAN cases remain regularly reported all over the world. Moreover, AAN incidence is probably highly underestimated given the presence of AA in traditional herbal remedies worldwide and the weak awareness of the disease. During these two past decades, animal models for AAN have been developed to investigate underlying molecular and cellular mechanisms involved in AAN pathogenesis. Indeed, a more-in-depth understanding of these processes is essential to develop therapeutic strategies aimed to reduce the global and underestimated burden of this disease. In this regard, our purpose was to build a broad overview of what is currently known about AAN. To achieve this goal, we aimed to summarize the latest data available about underlying pathophysiological mechanisms leading to AAN development with a particular emphasis on the imbalance between vasoactive factors as well as a focus on the vascular events often not considered in AAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.